Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.383 | An Optimization of Sourcing, Culturing and Preservation Procedures for Development of Mesenchymal Stem Cell Banking | Prof. LI Gang |
| 2020.395 | Comparing Focal Laser Photocoagulation and Subthreshold Micropulse Laser in Diabetic Macular Edema Using OCT Angiography |
Dr. LI Gabriel Ka Hin 李嘉軒 |
| 2015.225 | Slow-coagulation Cyclophotocoagulation for the Treatment of Refractory Glaucoma |
Dr. LI Felix Chi Hong 李志康 |
| 2010.463 | In vivo assessment of bone microarchitecture and bone perfusion in osteoporotic patients with systemic lupus erythematosus | Prof. Li Edmund Kwok-ming |
| 2007.083 | Genetic Studies of Autoimmune Disease in Chinese | Prof. LI Edmund Kwok Ming |
| 2010.298 | A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis | Professor Li Edmund Kwok Ming |
| 2011.228 | Effects of inflammation on bone loss in rheumatoid arthritis: Does inflammation affect joints and bone equally? | Professor LI Edmund K |
| 2011.570 | Bone quality in men with rheumatoid arthritis: A case-control study using the high-resolution peripheral quantitative computed tomography | Prof. Li Edmund K |
| 2010.455 | A prospective case-control cost of illness studies in systemic lupus erythematosus | Prof. LI Edmund K |
| 2011.509 | In vivo assessment of periaricular and generalized bone loss in patients with rheumatoid arthritis by high resolution peripheral quantitative computed tomography | Prof. LI Edmund |
| 2021.325 | Repetitive Negative Thinking of Patients with Common Mental Disorders: The Role of Goal Discrepancy, Rationality, and Psychological Flexibility |
Ms. LI Connie Suk Man 李淑雯 |
| 2022.680 | A retrospective study on clinical characteristics and treatment outcomes in patients with acquired haemophilia A (AHA) in Hong Kong | Dr. LI Chung Hin |
| 2022.441 | Impact of pre-operative penicillin allergy evaluation on surgical prophylaxis: a randomized controlled trial | Dr. LI Chun Man |
| 2013.394 | Development and Testing of a Self-management Model for Patients with Chronic Obstructive Pulmonary Disease | Miss LI CHING CHING |
| 2021.314 | Effect of cancer treatment in adolescents and early adults on uterus and endometrial function |
Prof Li Chi Kong 李志光 |
| 2021.110 | Effect of cancer treatment on testicular function and semen quality in male childhood and adolescent cancer survivors |
Prof LI Chi Kong 李志光 |
| 2021.280 | Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
| 2013.482 | Oral Arsenic trioxide in Management of Newly Diagnosed and Relapsed or refractory Acute Promyelocytic Leukemia (PML/RARα) in Children | Dr. LI Chi Kong |
| 2008.077 | A Multi-center Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008 | Dr Li Chi Kong |
| 2008.423 | Pilot Study of Efficacy and Safety of Chinese Herbal Medicine Gualou (Fructus Trichosanthis) in Treating Beta-thalassaemia Intermedia Patients | Prof Li Chi Kong |
| 2009.330 | A cross-sectional, multi-center, epidemiological study in Western and Asian countries in children and adolescents with Chronic Hepatitis B | Professor Li Chi Kong |
| 2011.607 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B | Dr. Li Chi Kong |
| 2011.606 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A | Dr. Li Chi Kong |
| 2013.047 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. LI Chi Kong |
| 2005.401 | International Collaborative Treatment Protocol for Infants Under One Year with Acute Lymphoblastic or Biphenotypic Leukemia | Dr. LI Chi Kong |
| 2010.064 | A Prospective, Open-label, Non-comparative Study to Assess the Safety, Tolerability and Efficacy of Voriconazole for the Primary and Salvage Treatment of Invasive Candidiasis, Candidemia, and Esophageal Candidiasis in Pediatric subjects | Dr. LI CHI KONG |
| 2007.361 | An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) | Dr. LI Chi Kong |
| 2015.023 | Acute Lymphoblastic Leukaemia, Chinese Children Cancer Leukaemia Group 2015 Study | Dr. LI Chi Kong |
| 2017.610 | To study the effect of Syk inhibition or deletion on terminal erythropoiesis of human thalassemic hematopoietic and stem progenitors |
Prof. LI Chi Kong 李志光教授 |
| 2016.406 | Genomic study on inherited bone marrow failure syndromes in Hong Kong by next generation sequencing |
Prof. LI Chi Kong 李志光 |
| 2016.643 | Genotyping variants determining mercaptopurine tolerance in Chinese children with Acute Lymphoblastic Leukaemia |
Prof. LI Chi Kong 李志光 |
| 2017.131 | Asparaginase activity and inhibitor in Chinese patients |
Prof. LI Chi Kong 李志光教授 |
| 2014.462 | Phase II Trial of the Addition of Gemcitabine to 131I-MIBG Therapy in Paediatric Patients with Relapsed or Progressive Neuroblastoma | Dr. LI Chi Kong |
| 2017.625 | International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones: EsPhALL2017/COGAALL1631 |
Prof. LI Chi Kong 李志光 |
| 2017.012 | Asian-wide, multicenter open-label, phase II non-randomised study involving children with Down syndrome under 21 year-old with newly diagnosed, treatment naïve acute lymphoblastic leukemia |
Prof. LI Chi Kong 李志光 |
| 2016.247 | Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%) |
Dr. LI Chi Kong 李志光 |
| 2017.568 | An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma |
Prof. LI Chi Kong 李志光教授 |
| 2015.286 | A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A |
Dr. LI Chi Kong 李志光 |
| 2017.178 | A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia |
Prof. LI Chi Kong 李志光教授 |
| 2017.241 | Non-interventional Study on the Safety and Efficacy of Micafungin for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania – ERADICATE Study |
Prof. LI Chi Kong 李志光 |
| 2017.355 | miRNA as diagnostic biomarkers for early detection of brain damage in acute leukaemia |
Prof. LI Chi Kong 李志光 |
| 2017.606 | A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab versus no Prophylaxis in Hemophilia A Patients |
Prof. LI Chi Kong 李志光 |
| 2014.364 | A Phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pediatric patients with severe hemophilia A | Dr. LI Chi Kong |
| 2017.607 | Chinese Children Cancer Group Relapsed ALL 2017 Study |
Prof. LI Chi Kong 李志光 |
| 2015.631 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. LI Chi Kong 李志光醫生 |
| 2017.440 | The prevalence and clinical outcome of Ph-like Acute Lymphoblastic Leukaemia in a retrospective cohort |
Prof. LI Chi Kong 李志光 |
| 2010.106 | International Study of chronic myelod leukaemia (CML) Treatment and Outcomes in Children and Adolescents | Dr. LI CHI KONG |
| 2013.307 | Preclinical evaluation of CD9 as a target for treatment of pediatric B-cell acute lymphoblastic leukemia via modulations of migration and engraftment activities | Dr. LI Chi Kong |
| 2012.448 | Role and reguatory signals of novel genes RGS1 and RGS13 in the homing and engraftment of human hematopoietic stem/progenitor cells for bone marrow immunologic reconstitution | Dr. LI Chi Kong |
| 2012.477 | Promotion of cord blood stem cell homing/engraftment by enhancing the expression of a novel tetraspanin protein CD9 | Dr. LI Chi Kong |
Page 114 of 262.